The European Commission announced on Wednesday that it had reached a preliminary agreement to obtain two hundred million doses of a possible vaccine against the emerging corona virus developed by the German-American alliance "Biontech / Pfizer", with the possibility of obtaining One hundred million additional doses, in the sixth agreement of its kind concluded by the European Union.
"The final negotiations with Biontec / Pfizer are making new progress to strengthen our solid and diverse offer of potential vaccines," European Commissioner for Health Stella Kyriakides said in a statement.
"We are optimistic that one of these vaccines against COVID-19 can prove safe and effective, to help us overcome this pandemic," she added.
The company "Biontech" and "Pfizer" American laboratories have been developing this vaccine months ago, which entered the phase of large-scale clinical trials at the end of July. In early July, the coalition disclosed positive initial results after testing 45 people.
On July 22, the United States announced the payment of 1.95 billion dollars to obtain a hundred million doses of the potential vaccine developed from the German-American alliance. Japan also signed an agreement with the two companies to secure 120 million doses.
This is the sixth agreement of its kind for the European Union, which previously agreed with the French-British consortium "Sanofi-GSK", the American laboratories "Johnson & Johnson", the German "Corvac" and the American biotechnology company "Moderna" to ensure the reservation of a large number of doses.
On August 14, the European Commission signed an agreement providing for the prior purchase of three hundred million doses from the Swedish-British pharmaceutical group "AstraZeneca", with the possibility of obtaining an additional 100 million doses.
